6.
Austin J, Cebrun H, Kershisnik M, El-Naggar A, Garden A, Demonte F
. Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the m.d. Anderson cancer center. Skull Base Surg. 1996; 6(1):1-8.
PMC: 1656508.
DOI: 10.1055/s-2008-1058907.
View
7.
Matula C, Roessler K, Burian M, Schuster H, Trattnig S, Hainfellner J
. Primary neuroendocrine (merkel cell) carcinoma of the anterior skull base. Skull Base Surg. 1997; 7(3):151-8.
PMC: 1656637.
DOI: 10.1055/s-2008-1058607.
View
8.
Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J
. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72.
DOI: 10.1200/JCO.2007.15.4377.
View
9.
Ibrahim M, Yousef M, Bohnen N, Eisbruch A, Parmar H
. Primary carcinoid tumor of the skull base: case report and review of the literature. J Neuroimaging. 2008; 20(4):390-2.
DOI: 10.1111/j.1552-6569.2008.00317.x.
View
10.
Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M
. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656-63.
DOI: 10.1200/JCO.2009.22.8510.
View
11.
Pavel M, Grossman A, Arnold R, Perren A, Kaltsas G, Steinmuller T
. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology. 2010; 91(4):326-32.
DOI: 10.1159/000287277.
View
12.
Chamoun R, DeMonte F
. Management of skull base metastases. Neurosurg Clin N Am. 2010; 22(1):61-6, vi-ii.
DOI: 10.1016/j.nec.2010.08.005.
View
13.
Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J
. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011; 117(15):3332-41.
DOI: 10.1002/cncr.25855.
View
14.
Oberg K, Knigge U, Kwekkeboom D, Perren A
. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii124-30.
DOI: 10.1093/annonc/mds295.
View
15.
Mallory G, Fang S, Giannini C, Van Gompel J, Parney I
. Brain carcinoid metastases: outcomes and prognostic factors. J Neurosurg. 2013; 118(4):889-95.
DOI: 10.3171/2013.1.JNS121556.
View
16.
Araujo P, Cheng S, Mete O, Serra S, Morin E, Asa S
. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One. 2013; 8(4):e61538.
PMC: 3631242.
DOI: 10.1371/journal.pone.0061538.
View
17.
Caplin M, Pavel M, Cwikla J, Phan A, Raderer M, Sedlackova E
. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(3):224-33.
DOI: 10.1056/NEJMoa1316158.
View
18.
Pavel M, OToole D, Costa F, Capdevila J, Gross D, Kianmanesh R
. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016; 103(2):172-85.
DOI: 10.1159/000443167.
View
19.
GREENBERG H, Deck M, Vikram B, Chu F, Posner J
. Metastasis to the base of the skull: clinical findings in 43 patients. Neurology. 1981; 31(5):530-7.
DOI: 10.1212/wnl.31.5.530.
View